Please login to the form below

Not currently logged in
Email:
Password:

Genmab

This page shows the latest Genmab news and features for those working in and with pharma, biotech and healthcare.

Celgene’s Revlimid cleared for aggressive lymphoma type in EU

Celgene’s Revlimid cleared for aggressive lymphoma type in EU

New launches such as Johnson &Johnson/Genmab's Darzalex (daratumumab) and Novartis' Farydak (panobinostat) are currently targeting relapsed myeloma but are expected to shift to earlier-stage treatment.

Latest news

  • Bristol-Myers Squibb acquires Cormorant for $520m Bristol-Myers Squibb acquires Cormorant for $520m

    Based at the Karolinska Institute Science Park in Stockholm, Cormorant focuses on cancer and rare diseases, and itself bought the rights to HuMax-IL8 by Genmab in 2012 under an exclusive

  • J&J gets European OK for myeloma therapy Darzalex J&J gets European OK for myeloma therapy Darzalex

    Darzalex - originally developed by Denmark's Genmab - is currently in a phase III trial comparing the combination of the antibody with bortezomib and dexamethasone to bortezomib and dexamethasone alone, and achieved

  • GSK gene therapy tops CHMP recommendations GSK gene therapy tops CHMP recommendations

    Originally developed by Genmab, the first-in-class anti-CD38 monoclonal antibody has been approved for use in patients whose previous treatment included proteasome inhibitor Takeda's Velcade (bortezomib) and an

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    The four are Genmab/Johnson &Johnson's Darzalex (daratumumab), AbbVie/Bristol-Myers Squibb's Empliciti (elotuzumab), Takeda's Ninlaro (ixazomib) and Novartis' Farydak (panobinostat), the first HDAC inhibitor to be approved ... Switzerland. daratumumab.

  • J&J gets FDA green light for myeloma drug Darzalex J&J gets FDA green light for myeloma drug Darzalex

    Approval of daratumumab triggers a $45m payment from Janssen to Denmark's Genmab, which originally discovered the drug and licensed it to J&J in a $1.1bn deal. ... J&J and Genmab are also working on a subcutaneous formulation of daratumumab which has

More from news
Approximately 4 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    469. Genmab (DK). Gilead (US). Licence. DuoBody technology platform to develop bispecific antibody candidates for targeting HIV plus option to second licence.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Exclusive global licence. 510. Genmab. Novo Nordisk. Bispecific antibody candidates outside oncology indications.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Four years ago Genmab started working with Seattle Genetics' ADC technology and has now signed a new deal using a Genmab antibody. ... The creative aspect of this deal is that Seattle has retained an option to increase the Genmab royalties to double

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    23. Genmab/ Janssen. Milestone payment. Daratumumab, anti-CD38 mAb for multiple myeloma (p2 milestone).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • EUSA Pharma appoints Rolf Hoffmann to its board EUSA Pharma appoints Rolf Hoffmann to its board

    Hoffman, who is currently chairman of Biotest and sits on the board of directors of Genmab, brings over 30 years’pharmaceutical experience to his new position having served in a number

  • Dr Jan van de Winkel joins Austrian biotech Hookipa Dr Jan van de Winkel joins Austrian biotech Hookipa

    Current president and chief executive officer of Genmab, Dr van de Winkel joins the board with over 25 years’experience in the therapeutic antibody field. ... Dr van de Winkel’s career experience has seen him serve Medarex Europe as its vice

  • Former Novartis exec joins Genmab Former Novartis exec joins Genmab

    Copenhagen, Denmark-based Genmab has appointed Dr Judith Klimovsky as executive vice president and chief development officer. ... Jan van de Winkel, Genmab's chief executive, said: “ We are very pleased to welcome Judith to Genmab. “

  • bmore creative hires Kush Rach as new business director bmore creative hires Kush Rach as new business director

    at Charles River Laboratories, where he worked on clinical trial programmes for Ferring, Genmab, AstraZeneca, and Aerocrine (spending much of his time in Scandinavia).

  • Agneta Svedberg appointed COO at Zealand Pharma Agneta Svedberg appointed COO at Zealand Pharma

    Svedberg has more than 20 years of experience in the industry, most of which has been spent in northern Europe and includes a ten-year spell with Genmab in Denmark, where

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics